Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Rallybio ( (RLYB) ) is now available.
On May 13, 2025, Rallybio Corporation held its annual shareholder meeting where Martin W. Mackay and Paula Soteropoulos were elected as Class I directors for terms ending in 2028. Additionally, shareholders ratified Deloitte and Touche LLP as the independent public accounting firm for the fiscal year ending December 31, 2025, signaling continued confidence in the company’s financial oversight.
The most recent analyst rating on (RLYB) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.
Spark’s Take on RLYB Stock
According to Spark, TipRanks’ AI Analyst, RLYB is a Underperform.
Rallybio’s stock is under significant pressure due to poor financial performance characterized by operational losses and negative cash flows, compounded by bearish technical indicators and challenging valuation metrics. Without revenue growth, the sustainability of operations is at risk, making it a highly speculative investment in its current state.
To see Spark’s full report on RLYB stock, click here.
More about Rallybio
Rallybio Corporation operates in the biotechnology industry, focusing on developing and commercializing therapies for rare diseases.
Average Trading Volume: 104,604
Technical Sentiment Signal: Sell
Current Market Cap: $12.88M
Find detailed analytics on RLYB stock on TipRanks’ Stock Analysis page.